Heska (Loveland, CO; Nasdaq: HSKA), a veterinary diagnostics company has signed a product development partnership and licensing agreement with MBio Diagnostics (Boulder, CO), which develops rapid clinical diagnostics and sample testing. MBio and Heska will jointly carry out product development based on the MBio Array System, which uses its LightDeck technology to enable simple, multiplex testing in a compact system.
The Array System will be paired with Heska’s reagents to enable multiplexed, high sensitivity assays directly in the vet clinic without sending to a reference laboratory. For example, it will enable tests for vector-borne diseases, parasitology, and animal health and wellness. The system is based on optical planar waveguide technology that eliminates sample prep and can be designed to detect all key analytes, including proteins, cells, nucleic acids, and small molecules.
According to MBio CEO Chris Myatt; “Commercialization partnerships are an important aspect of our business strategy. We have made enormous progress advancing our platform technology in recent years, and we are now executing on strategic partnerships that open new high-value opportunities.” The company aims to serve providers and users of clinical and analytical testing services in all market segments, including medical, veterinary, environmental, food, agricultural and military.
Source: MBio Diagnostics